Industry & Business

Pretax losses double at Dublin-listed Merrion Pharmaceuticals

 Breaking News
  • ASAI Issues New Guidelines For Advertising Mobile Phone and Broadband Services The Advertising Standards Authority for Ireland (ASAI), the independent self-regulatory body committed to promoting the highest standards of marketing communications in Ireland, has introduced new guidelines relating to the advertising of mobile phone and broadband services. The guidelines will complement the existing ASAI Code in ensuring that certain marketing terms used by telecommunications operators convey [...]...
  • Sustainable Apartment Living For Ireland A new report on sustainable apartment living in Ireland was launched by the Housing Agency and Clúid Housing. Amongst some of the reports findings and research were that apartment living has increased in the last few years and according to the report, the number of apartments in Ireland has increased by 85% between 2002 and [...]...
  • Brand New Campaign Showcasing Ireland’s Food and Drink Starts Fáilte Ireland’s Taste the Island campaign has gone live with a brand-new TV ad encouraging domestic holidaymakers to take a short break in Ireland to enjoy some of the 700+ food and drink related experiences on offer across this September, October and November. Taste the Island is a 12-week celebration of Ireland’s seasonal ingredients, adventurous tastes [...]...
  • Enet Expands its Data Centre Connectivity Portfolio Across Dublin Enet, Ireland’s largest wholesale, open-access network provider, has added six more data centres across Dublin to its national network. The additional data centres allow it to offer more options when it comes to dark fibre and managed bandwidth to its customers, and will result in increased connectivity for consumers. Enet is now connected to 25 data [...]...
  • ACCA and Bank of Ireland Issue Warning Amid Foreign Currency Fluctuations Many Irish companies that deal in foreign currency are exposing their businesses to significant and unnecessary profitability risks due to a lack of consideration of appropriate hedging within their organisations. That’s the message from the Association of Chartered Certified Accountants (ACCA) and Bank of Ireland who have launched a new programme to support businesses in [...]...

Pretax losses double at Dublin-listed Merrion Pharmaceuticals

Pretax losses double at Dublin-listed Merrion Pharmaceuticals
October 02
09:19 2015

Merrion Pharmaceuticals says its survival is dependent on Declan Ryan’s Irelandia Investments not calling in an overdue loan as it reported a doubling of half-year losses.

The Dublin-listed group, whose Irish revenue comes through two licence agreements with Danish diabetes specialist Novo Nordisk, reported a net loss of €1.02 million or €5.58 cent per share for the six months to the end of June. This compares to a loss of €507,000 or €2.76 cents for the same period a year earlier.

The decline was largely due to a €705,000 drop in revenue from €955,793 to €250,000.

For the same period last year, Merrion’s revenues were boosted by a €727,000 milestone payment from Novo Nordisk on completion of a single dose Phase 1 trial with a novel oral insulin.

Administrative and research and development declined by €440,000 from €1 million to €561,000 from June 2014 to the same month this year. Net finance expenses rose by €276,000 from €454,000 to €716,000 over the same period, due in part to foreign exchange losses.

Established in 2003, Merrion is engaged in developing oral forms of drugs that typically have poor absorption and are generally given by injection.

In its interim statement the group said its ability to generate sufficient cash to repay a €4.8 million loan to Irelandia “cast significant doubt on the ability of the group to continue as a going concern for the foreseeable future.”

Repayment of the loan was originally due to be made in December. At the end of March Irelandia agreed to extend the principal repayment term by 18 months to the end of September with the deferred interest of €167,569 remaining payable aby June 30th. It has since said though that it has no intention of calling in repayment of the laon before the end of this year.

Merrion said that notwithstanding the uncertainty over the loan repayment its directors had a “reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future.”

Chairman Michael McKenna said the company continues to be encouraged by the success of Novo Nordisk in employing Merrion’s technology in the development of treatment of diabetes using oral medication.

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4